Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 705 shares of the stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $89.55, for a total value of $63,132.75. Following the transaction, the chief financial officer now directly owns 71,397 shares of the company's stock, valued at $6,393,601.35. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.
- On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
- On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
- On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
- On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.
- On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.
- On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total value of $210,566.15.
Natera Stock Up 0.4 %
Dems have chosen Biden replacement?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
NASDAQ NTRA opened at $91.66 on Friday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82. The stock's 50 day moving average is $87.72 and its two-hundred day moving average is $67.16. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. As a group, equities analysts expect that Natera, Inc. will post -2.35 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. The Goldman Sachs Group raised their target price on shares of Natera from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Monday, April 15th. Craig Hallum started coverage on Natera in a research note on Monday, April 8th. They set a "buy" rating and a $117.00 target price for the company. StockNews.com downgraded Natera from a "hold" rating to a "sell" rating in a research report on Tuesday. BTIG Research increased their price objective on Natera from $75.00 to $85.00 and gave the company a "buy" rating in a research report on Friday, December 29th. Finally, Raymond James downgraded shares of Natera from a "strong-buy" rating to an "outperform" rating and raised their price objective for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $86.40.
View Our Latest Stock Report on Natera
Institutional Investors Weigh In On Natera
A number of hedge funds have recently made changes to their positions in the company. Norges Bank bought a new stake in Natera during the fourth quarter worth about $83,970,000. American Century Companies Inc. grew its position in Natera by 115.7% during the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company's stock worth $73,203,000 after acquiring an additional 887,409 shares during the last quarter. Invesco Ltd. increased its holdings in Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company's stock valued at $111,930,000 after purchasing an additional 865,404 shares in the last quarter. Perceptive Advisors LLC increased its holdings in Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company's stock valued at $53,258,000 after purchasing an additional 632,047 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company's stock valued at $687,280,000 after purchasing an additional 588,147 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Natera Company Profile
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
